Literature DB >> 29117355

Current Gaps in Ovarian Cancer Epidemiology: The Need for New Population-Based Research.

Jennifer A Doherty1, Allan Jensen1, Linda E Kelemen1, Celeste L Pearce1, Elizabeth Poole1, Joellen M Schildkraut1, Kathryn L Terry1, Shelley S Tworoger1, Penelope M Webb1, Nicolas Wentzensen1.   

Abstract

With recent ovarian cancer screening studies showing no clinically significant mortality benefit, preventing this disease, identifying high-risk populations, and extending survival remain priorities. However, several challenges are impeding progress in ovarian cancer research. With most studies capturing exposure information from 10 or more years ago, evaluation of how changing patterns of exposures, such as new oral contraceptive formulations and increased intrauterine device use, might influence ovarian cancer risk and survival is difficult. Risk factors for ovarian cancer should be evaluated in the context of tumor histotypes, which have unique molecular features and cells of origin; this is a task that requires large collaborative studies to achieve meaningful sample sizes. Importantly, identification of novel modifiable risk factors, in addition to those currently known to reduce risk (eg, childbearing, tubal ligation, oral contraceptive use), is needed; this is not feasibly implemented at a population level. In this Commentary, we describe important gaps in knowledge and propose new approaches to advance epidemiologic research to improve ovarian cancer prevention and survival, including updated classification of tumors, collection of data on changing and novel exposures, longer follow-up on existing studies, evaluation of diverse populations, development of better risk prediction models, and collaborating prospectively with consortia to develop protocols for new studies that will allow seamless integration for future pooled analyses.
© The Author 2017. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29117355      PMCID: PMC6279295          DOI: 10.1093/jnci/djx144

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  84 in total

1.  Hormonal and reproductive factors and the risk of ovarian cancer.

Authors:  Anita Koushik; Anne Grundy; Michal Abrahamowicz; Jocelyne Arseneau; Lucy Gilbert; Walter H Gotlieb; Julie Lacaille; Anne-Marie Mes-Masson; Marie-Élise Parent; Diane M Provencher; Lesley Richardson; Jack Siemiatycki
Journal:  Cancer Causes Control       Date:  2017-01-19       Impact factor: 2.506

2.  C-reactive protein concentrations and subsequent ovarian cancer risk.

Authors:  Meghan A McSorley; Anthony J Alberg; Diane S Allen; Naomi E Allen; Louise A Brinton; Joanne F Dorgan; Michael Pollak; Yuzhen Tao; Kathy J Helzlsouer
Journal:  Obstet Gynecol       Date:  2007-04       Impact factor: 7.661

3.  Low-dose aspirin use and the risk of ovarian cancer in Denmark.

Authors:  L Baandrup; S K Kjaer; J H Olsen; C Dehlendorff; S Friis
Journal:  Ann Oncol       Date:  2014-12-23       Impact factor: 32.976

4.  Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.

Authors:  Siân Jones; Tian-Li Wang; Ie-Ming Shih; Tsui-Lien Mao; Kentaro Nakayama; Richard Roden; Ruth Glas; Dennis Slamon; Luis A Diaz; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Nickolas Papadopoulos
Journal:  Science       Date:  2010-09-08       Impact factor: 47.728

5.  Risk Prediction for Epithelial Ovarian Cancer in 11 United States-Based Case-Control Studies: Incorporation of Epidemiologic Risk Factors and 17 Confirmed Genetic Loci.

Authors:  Merlise A Clyde; Rachel Palmieri Weber; Edwin S Iversen; Elizabeth M Poole; Jennifer A Doherty; Marc T Goodman; Roberta B Ness; Harvey A Risch; Mary Anne Rossing; Kathryn L Terry; Nicolas Wentzensen; Alice S Whittemore; Hoda Anton-Culver; Elisa V Bandera; Andrew Berchuck; Michael E Carney; Daniel W Cramer; Julie M Cunningham; Kara L Cushing-Haugen; Robert P Edwards; Brooke L Fridley; Ellen L Goode; Galina Lurie; Valerie McGuire; Francesmary Modugno; Kirsten B Moysich; Sara H Olson; Celeste Leigh Pearce; Malcolm C Pike; Joseph H Rothstein; Thomas A Sellers; Weiva Sieh; Daniel Stram; Pamela J Thompson; Robert A Vierkant; Kristine G Wicklund; Anna H Wu; Argyrios Ziogas; Shelley S Tworoger; Joellen M Schildkraut
Journal:  Am J Epidemiol       Date:  2016-10-03       Impact factor: 4.897

6.  Reproductive factors and ovarian cancer risk in African-American women.

Authors:  Patricia G Moorman; Anthony J Alberg; Elisa V Bandera; Jill Barnholtz-Sloan; Melissa Bondy; Michele L Cote; Ellen Funkhouser; Edward S Peters; Ann G Schwartz; Paul Terry; Sydnee Crankshaw; Frances Wang; Joellen M Schildkraut
Journal:  Ann Epidemiol       Date:  2016-07-18       Impact factor: 3.797

7.  Is Pelvic Inflammatory Disease a Risk Factor for Ovarian Cancer?

Authors:  Christina B Rasmussen; Allan Jensen; Vanna Albieri; Klaus K Andersen; Susanne K Kjaer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-09-26       Impact factor: 4.254

8.  Hypertension, use of antihypertensive medications, and risk of epithelial ovarian cancer.

Authors:  Tianyi Huang; Elizabeth M Poole; A Heather Eliassen; Olivia I Okereke; Laura D Kubzansky; Anil K Sood; John P Forman; Shelley S Tworoger
Journal:  Int J Cancer       Date:  2016-03-25       Impact factor: 7.396

9.  Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland.

Authors:  Tuuli Soini; Ritva Hurskainen; Seija Grénman; Johanna Mäenpää; Jorma Paavonen; Eero Pukkala
Journal:  Obstet Gynecol       Date:  2014-08       Impact factor: 7.661

10.  Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium.

Authors:  Britton Trabert; Roberta B Ness; Wei-Hsuan Lo-Ciganic; Megan A Murphy; Ellen L Goode; Elizabeth M Poole; Louise A Brinton; Penelope M Webb; Christina M Nagle; Susan J Jordan; Harvey A Risch; Mary Anne Rossing; Jennifer A Doherty; Marc T Goodman; Galina Lurie; Susanne K Kjær; Estrid Hogdall; Allan Jensen; Daniel W Cramer; Kathryn L Terry; Allison Vitonis; Elisa V Bandera; Sara Olson; Melony G King; Urmila Chandran; Hoda Anton-Culver; Argyrios Ziogas; Usha Menon; Simon A Gayther; Susan J Ramus; Aleksandra Gentry-Maharaj; Anna H Wu; Celeste Leigh Pearce; Malcolm C Pike; Andrew Berchuck; Joellen M Schildkraut; Nicolas Wentzensen
Journal:  J Natl Cancer Inst       Date:  2014-02       Impact factor: 11.816

View more
  12 in total

1.  The influence of birth cohort and calendar period on global trends in ovarian cancer incidence.

Authors:  Citadel J Cabasag; Melina Arnold; John Butler; Manami Inoue; Britton Trabert; Penelope M Webb; Freddie Bray; Isabelle Soerjomataram
Journal:  Int J Cancer       Date:  2019-04-30       Impact factor: 7.396

2.  Antibodies Against Chlamydia trachomatis and Ovarian Cancer Risk in Two Independent Populations.

Authors:  Britton Trabert; Tim Waterboer; Annika Idahl; Nicole Brenner; Louise A Brinton; Julia Butt; Sally B Coburn; Patricia Hartge; Katrin Hufnagel; Federica Inturrisi; Jolanta Lissowska; Alexander Mentzer; Beata Peplonska; Mark E Sherman; Gillian S Wills; Sarah C Woodhall; Michael Pawlita; Nicolas Wentzensen
Journal:  J Natl Cancer Inst       Date:  2019-02-01       Impact factor: 13.506

3.  Epidemiologic paradigms for progress in ovarian cancer research.

Authors:  Shelley S Tworoger; Jennifer Anne Doherty
Journal:  Cancer Causes Control       Date:  2017-05       Impact factor: 2.506

4.  Cohort Profile: The Ovarian Cancer Cohort Consortium (OC3).

Authors:  Mary K Townsend; Britton Trabert; Renée T Fortner; Alan A Arslan; Julie E Buring; Brian D Carter; Graham G Giles; Sarah R Irvin; Michael E Jones; Rudolf Kaaks; Victoria A Kirsh; Synnove F Knutsen; Woon-Puay Koh; James V Lacey; Hilde Langseth; Susanna C Larsson; I-Min Lee; María Elena Martínez; Melissa A Merritt; Roger L Milne; Katie M O'Brien; Michael J Orlich; Julie R Palmer; Alpa V Patel; Ulrike Peters; Jenny N Poynter; Kim Robien; Thomas E Rohan; Lynn Rosenberg; Sven Sandin; Dale P Sandler; Leo J Schouten; V Wendy Setiawan; Anthony J Swerdlow; Giske Ursin; Piet A van den Brandt; Kala Visvanathan; Elisabete Weiderpass; Alicja Wolk; Jian-Min Yuan; Anne Zeleniuch-Jacquotte; Shelley S Tworoger; Nicolas Wentzensen
Journal:  Int J Epidemiol       Date:  2022-06-13       Impact factor: 9.685

5.  miR-197-3p reduces epithelial-mesenchymal transition by targeting ABCA7 in ovarian cancer cells.

Authors:  Weiquan Xie; Chengyu Shui; Xiping Fang; Yuqiu Peng; Li Qin
Journal:  3 Biotech       Date:  2020-08-04       Impact factor: 2.406

6.  Joint IARC/NCI International Cancer Seminar Series Report: expert consensus on future directions for ovarian carcinoma research.

Authors:  Shama Virani; Glauco Baiocchi; David Bowtell; Citadel J Cabasag; Kathleen R Cho; Renée T Fortner; Keiichi Fujiwara; Jae-Weon Kim; Martin Köbel; Jean-Emmanuel Kurtz; Douglas A Levine; Usha Menon; Barbara M Norquist; Paul D P Pharoah; Anil K Sood; Shelley T Tworoger; Nicolas Wentzensen; Stephen J Chanock; Paul Brennan; Britton Trabert
Journal:  Carcinogenesis       Date:  2021-06-21       Impact factor: 4.944

7.  Risks of female genital tract related cancers (gynecological cancers) or breast cancer in women with and without chronic kidney disease: A population-based cohort study in Taiwan.

Authors:  Wen-Hsun Chang; Huann-Cheng Horng; Chang-Ching Yeh; Chao-Yu Guo; Yiing-Jeng Chou; Nicole Huang; Hsin-Yi Huang; Yi-Jen Chen; Wen-Ling Lee; Peng-Hui Wang
Journal:  Medicine (Baltimore)       Date:  2018-03       Impact factor: 1.889

8.  Appraising the role of previously reported risk factors in epithelial ovarian cancer risk: A Mendelian randomization analysis.

Authors:  James Yarmolinsky; Caroline L Relton; Artitaya Lophatananon; Kenneth Muir; Usha Menon; Aleksandra Gentry-Maharaj; Axel Walther; Jie Zheng; Peter Fasching; Wei Zheng; Woo Yin Ling; Sue K Park; Byoung-Gie Kim; Ji-Yeob Choi; Boyoung Park; George Davey Smith; Richard M Martin; Sarah J Lewis
Journal:  PLoS Med       Date:  2019-08-07       Impact factor: 11.069

9.  Circular RNA ABCB10 promotes cell proliferation and invasion, but inhibits apoptosis via regulating the microRNA‑1271‑mediated Capn4/Wnt/β‑catenin signaling pathway in epithelial ovarian cancer.

Authors:  Xuefang Lin; Yan Chen; Xiabin Ye; Xuemei Xia
Journal:  Mol Med Rep       Date:  2021-03-24       Impact factor: 2.952

10.  Lifestyle and reproductive health: the aetiology of ovarian cancer in Pakistan.

Authors:  Qurratulann Alvi; Gul Muhammad Baloch; Karuthan Chinna; Ali Dabbagh
Journal:  F1000Res       Date:  2020-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.